⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31140820 | 1.00 | — | — | |
| SCHEMBL25317458 | 0.80 | MAOB (0.35) | — | |
| SCHEMBL31140819 | 0.80 | MAOB (0.35) | — | |
| SCHEMBL31140818 | 0.78 | — | — | |
| SCHEMBL25317695 | 0.78 | CTSC (0.33) | — | |
| SCHEMBL31140836 | 0.78 | CTSC (0.33) | — | |
| SCHEMBL25318459 | 0.78 | — | — | |
| SCHEMBL25318693 | 0.77 | NPC1 (0.40) | — | |
| SCHEMBL31140806 | 0.77 | NPC1 (0.40) | — | |
| SCHEMBL25901195 | 0.77 | NPC1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115572-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS PHARMA AG (CH) | 2025-04-10 | — | — | US | disclosed |
| EP-4469157-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| CN-118696035-A | Spiropiperidyl derivatives as complement factor B inhibitors and their use | 诺华股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2023139534-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139534-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-07-27 | — | — | WO | disclosed |